Maria Vitale
Industrial Farmaceutica Cantabria-IFC Group, Spain
Title: Assessment of the efficacy and tolerance of a new combination of retinoids and depigmenting agents in the treatment of melasma
Biography
Biography: Maria Vitale
Abstract
Melasma is a common hyperpigmentation disorder which mainly affects women with a high phototype and often remains active for several years, being associated with a considerable psychological impact. The management of melasma is often challenging, because it is very resistant to treatments and requires long-term therapeutic protocols. Conventional treatment includes depigmenting products, such as hydroquinone (HQ), retinoids, mequinol, azelaic acid, arbutin, kojic acid, etc., which exert their action at different stages of melanogenesis. In addition, avoidance of aggravating factors is strongly indicated. Combination therapy is usually prescribed, with a typical association of HQ and retinoic acid. However, HQ’s safety has been questioned in certain cases, and prolonged use may lead to adverse effects such as depigmentation and ochronosis, so it cannot be considered as a golden standard. In the search for safer alternatives, a new product based on RetinSphere® technology has been designed. It incorporates two topical retinoids: retinol glycospheres and hydroxypinacolone retinoate, which directly interacts with the retinoic acid receptor but does not induce irritation. Additionally, the product includes other depigmenting active ingredients. The objective has been creating a product which may reduce or even substitute the use of HQ in the management of melasma patients. We will show the results of clinical assays on several skin types and the efficacy and safety of the new combination of retinoids in the improvement of melasma will be discussed.
